- Home
- GLSI vs CCIF Comparison
GLSI vs CCIF Comparison
Compare GLSI & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- CCIF
- Stock Information
- Founded
- GLSI 2006
- CCIF 2011
- Country
- GLSI United States
- CCIF United States
- Employees
- GLSI N/A
- CCIF N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- GLSI Health Care
- CCIF Finance
- Exchange
- GLSI Nasdaq
- CCIF Nasdaq
- Market Cap
- GLSI 134.6M
- CCIF 113.2M
- IPO Year
- GLSI 2020
- CCIF N/A
- Fundamental
- Price
- GLSI $10.08
- CCIF $6.39
- Analyst Decision
- GLSI Strong Buy
- CCIF
- Analyst Count
- GLSI 1
- CCIF 0
- Target Price
- GLSI $39.00
- CCIF N/A
- AVG Volume (30 Days)
- GLSI 54.6K
- CCIF 76.9K
- Earning Date
- GLSI 08-13-2025
- CCIF 01-01-0001
- Dividend Yield
- GLSI N/A
- CCIF 25.90%
- EPS Growth
- GLSI N/A
- CCIF N/A
- EPS
- GLSI N/A
- CCIF N/A
- Revenue
- GLSI N/A
- CCIF N/A
- Revenue This Year
- GLSI N/A
- CCIF N/A
- Revenue Next Year
- GLSI N/A
- CCIF N/A
- P/E Ratio
- GLSI N/A
- CCIF N/A
- Revenue Growth
- GLSI N/A
- CCIF N/A
- 52 Week Low
- GLSI $8.06
- CCIF $7.43
- 52 Week High
- GLSI $17.00
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- GLSI 53.55
- CCIF 49.75
- Support Level
- GLSI $8.97
- CCIF $6.35
- Resistance Level
- GLSI $11.52
- CCIF $6.59
- Average True Range (ATR)
- GLSI 0.53
- CCIF 0.10
- MACD
- GLSI 0.14
- CCIF 0.02
- Stochastic Oscillator
- GLSI 49.53
- CCIF 68.13
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.